Insmed
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 82
- Registration Number
- NCT05927597
- Locations
- 🇺🇸
USA001, Glendale, California, United States
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 32
- Registration Number
- NCT05826574
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT05673603
- Locations
- 🇺🇸
USA003, Tampa, Florida, United States
🇺🇸USA001, San Antonio, Texas, United States
🇺🇸USA002, Orlando, Florida, United States
A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-brensocatib
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 7
- Registration Number
- NCT05652257
- Locations
- 🇺🇸
USA001, Madison, Wisconsin, United States
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Conditions
- Pulmonary HypertensionInterstitial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT05649722
- Locations
- 🇩🇪
GER010, Gießen, Hessen, Germany
🇩🇪GER012, Berlin, Germany
🇬🇧GBR001, Sheffield, South Yorkshire, United Kingdom
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 91
- Registration Number
- NCT05649748
- Locations
- 🇬🇧
GBR001, Bath, Avon, United Kingdom
🇷🇸SRB003, Belgrade, Serbia
🇪🇸ESP003, Sevilla, Spain
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 30
- Registration Number
- NCT05517525
- Locations
- 🇺🇸
USA002, Rialto, California, United States
🇺🇸USA003, Orlando, Florida, United States
🇺🇸USA001, San Antonio, Texas, United States
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT05355935
- Locations
- 🇺🇸
USA001, Madison, Wisconsin, United States
An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT05344508
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT05176951
- Locations
- 🇦🇺
AUS003, Camperdown, New South Wales, Australia
🇦🇺AUS005, Macquarie Park, New South Wales, Australia
🇧🇪BEL002, Liège, Belgium